801 related articles for article (PubMed ID: 23545756)
21. Monitoring high-dose heparinization during cardiopulmonary by-pass--a comparison between prothrombinase-induced clotting time (PiCT) and two chromogenic anti-factor Xa activity assays.
Raivio P; Kuitunen A; Petäjä J; Ilveskero S; Lassila R
Thromb Haemost; 2008 Feb; 99(2):427-34. PubMed ID: 18278195
[TBL] [Abstract][Full Text] [Related]
22. Clinical outcomes with unfractionated heparin monitored by anti-factor Xa vs. activated partial Thromboplastin time.
Coons JC; Iasella CJ; Thornberg M; Fitzmaurice MG; Goehring K; Jablonski L; Leader D; Meyer A; Seo H; Benedict NJ; Smith RE
Am J Hematol; 2019 Sep; 94(9):1015-1019. PubMed ID: 31243789
[TBL] [Abstract][Full Text] [Related]
23. Anti-factor Xa and activated partial thromboplastin time measurements for heparin monitoring in mechanical circulatory support.
Adatya S; Uriel N; Yarmohammadi H; Holley CT; Feng A; Roy SS; Reding MT; John R; Eckman P; Zantek ND
JACC Heart Fail; 2015 Apr; 3(4):314-22. PubMed ID: 25770404
[TBL] [Abstract][Full Text] [Related]
24. Anti-factor Xa assay is a superior correlate of heparin dose than activated partial thromboplastin time or activated clotting time in pediatric extracorporeal membrane oxygenation*.
Liveris A; Bello RA; Friedmann P; Duffy MA; Manwani D; Killinger JS; Rodriquez D; Weinstein S
Pediatr Crit Care Med; 2014 Feb; 15(2):e72-9. PubMed ID: 24335992
[TBL] [Abstract][Full Text] [Related]
25. Unfractionated heparin infusion for thromboprophylaxis in highest risk gastric bypass surgery.
F Shepherd M; Rosborough TK; Schwartz ML
Obes Surg; 2004 May; 14(5):601-5. PubMed ID: 15186625
[TBL] [Abstract][Full Text] [Related]
26. Comparison of anti-Xa and activated partial thromboplastin time monitoring for heparin dosing in patients with cirrhosis.
Fuentes A; Gordon-Burroughs S; Hall JB; Putney DR; Monsour HP
Ther Drug Monit; 2015 Feb; 37(1):40-4. PubMed ID: 24901494
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of weight-based dosing of unfractionated heparin in obese children.
Taylor BN; Bork SJ; Kim S; Moffett BS; Yee DL
J Pediatr; 2013 Jul; 163(1):150-3. PubMed ID: 23414664
[TBL] [Abstract][Full Text] [Related]
28. Establishing a new target range for unfractionated heparin for acute coronary syndromes.
Lee MS; Menon V; Schappert J; Wilentz JR; Singh V; Hochman JS
J Thromb Thrombolysis; 2004 Apr; 17(2):121-6. PubMed ID: 15306747
[TBL] [Abstract][Full Text] [Related]
29. Unfractionated heparin dosing in young infants: clinical outcomes in a cohort monitored with anti-factor Xa levels.
Schechter T; Finkelstein Y; Ali M; Kahr WH; Williams S; Chan AK; Deveber G; Brandão LR
J Thromb Haemost; 2012 Mar; 10(3):368-74. PubMed ID: 22244010
[TBL] [Abstract][Full Text] [Related]
30. Monitoring heparin therapy using activated partial thromboplastin time--results of a multicenter trial establishing the therapeutic range for SILIMAT, a reagent with high sensitivity to heparin.
Toulon P; Boutière B; Horellou MH; Trzeciak MC; Samama MM
Thromb Haemost; 1998 Jul; 80(1):104-8. PubMed ID: 9684794
[TBL] [Abstract][Full Text] [Related]
31. Interlaboratory variation in heparin monitoring: Lessons from the Quality Management Program of Ontario coagulation surveys.
Cuker A; Raby A; Moffat KA; Flynn G; Crowther MA
Thromb Haemost; 2010 Oct; 104(4):837-44. PubMed ID: 20664895
[TBL] [Abstract][Full Text] [Related]
32. Design and Implementation of an Anti-Factor Xa Heparin Monitoring Protocol.
Williams-Norwood T; Caswell M; Milner B; Vescera JC; Prymicz K; Ciszak AG; Ingle C; Lacey C; Stavrou EX
AACN Adv Crit Care; 2020 Jun; 31(2):129-137. PubMed ID: 32526007
[TBL] [Abstract][Full Text] [Related]
33. Monitoring Unfractionated Heparin (UFH) therapy: which Anti-Factor Xa assay is appropriate?
Ignjatovic V; Summerhayes R; Gan A; Than J; Chan A; Cochrane A; Bennett M; Horton S; Shann F; Lane G; Ross-Smith M; Monagle P
Thromb Res; 2007; 120(3):347-51. PubMed ID: 17118432
[TBL] [Abstract][Full Text] [Related]
34. Achieving target antifactor Xa activity with a heparin protocol based on sex, age, height, and weight.
Rosborough TK; Shepherd MF
Pharmacotherapy; 2004 Jun; 24(6):713-9. PubMed ID: 15222660
[TBL] [Abstract][Full Text] [Related]
35. Coagulation factor abnormalities related to discordance between anti-factor Xa and activated partial thromboplastin time in patients supported with continuous-flow left ventricular assist devices.
Adatya S; Sunny R; Fitzpatrick MJ; Colvin M; Thennapan T; John R; Dodge Zantek N; Pritzker M; Eckman P; Uriel N
J Heart Lung Transplant; 2016 Nov; 35(11):1311-1320. PubMed ID: 27836023
[TBL] [Abstract][Full Text] [Related]
36. Activated Partial Thromboplastin Time Versus Anti-Factor Xa Monitoring of Heparin Anticoagulation in Adult Venoarterial Extracorporeal Membrane Oxygenation Patients.
Kulig CE; Schomer KJ; Black HB; Dager WE
ASAIO J; 2021 Apr; 67(4):411-415. PubMed ID: 33769995
[TBL] [Abstract][Full Text] [Related]
37. Dosage, anticoagulant, and antithrombotic effects of heparin and low-molecular-weight heparin in the treatment of deep vein thrombosis.
Harenberg J; Stehle G; Blauth M; Huck K; Mall K; Heene DL
Semin Thromb Hemost; 1997; 23(1):83-90. PubMed ID: 9156415
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of Antifactor-Xa Heparin Assay and Activated Partial Thromboplastin Time Values in Patients on Therapeutic Continuous Infusion Unfractionated Heparin Therapy.
McLaughlin K; Rimsans J; Sylvester KW; Fanikos J; Dorfman DM; Senna P; Connors JM; Goldhaber SZ
Clin Appl Thromb Hemost; 2019; 25():1076029619876030. PubMed ID: 31530176
[TBL] [Abstract][Full Text] [Related]
39. Evaluating unfractionated heparin fixed dosing protocol and establishing an institutional therapeutic range for UFH in hospital setting in Jordan.
Tahaineh L; Albsoul-Younes A; Iflaifel M; Shehabi I
Clin Appl Thromb Hemost; 2014 Jan; 20(1):73-7. PubMed ID: 22949741
[TBL] [Abstract][Full Text] [Related]
40. Comparison between activated clotting time and anti-activated factor X activity for the monitoring of unfractionated heparin therapy in patients with aortic aneurysm undergoing an endovascular procedure.
Dieplinger B; Egger M; Luft C; Hinterreiter F; Pernerstorfer T; Haltmayer M; Mueller T
J Vasc Surg; 2018 Aug; 68(2):400-407. PubMed ID: 29571622
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
